

Press Release

The Ethypharm Group and the Kalceks sign an agreement to make four injectable pain-management* solutions available in the CNS field in Germany

Saint Cloud, France – 4th July 2019

The Ethypharm Group is announcing that, via its subsidiary in Germany, it has entered into an agreement with the Kalceks under which Ethypharm is obtaining exclusive distribution rights in Germany for injectables with a base of Dexketoprofen, Oxycodone, Hydromorphone and Midazolam.

“We are delighted to be able to count Kalceks among our partners. This new partnership is an opportunity for Ethypharm GmbH to extend its drug offer in the field of CNS and more specifically in pain management. We are proud to be able to offer German patients and healthcare professionals high-quality drugs that meet their needs” says Ruud Helwig, Managing Director of Ethypharm GmbH & VP Commercial Operations Europe.

Frédéric Molin, Executive Vice President Corporate Development, adds that, “The Ethypharm Group is seeking partnership opportunities in advanced development and commercial products, in the fields of the CNS (Pain, Addiction) and Critical Care as our top priorities for Europe. We put all our skills and knowledge at our partners’ disposal in the fields of Development, Regulatory Controls, Market Access, Sales and Marketing, and Industrial Production.”

CEO of Kalceks, Juris Hmelnickis Ph.D., adds that, “Kalceks highly appreciate cooperation with Ethypharm and are sure that it is just the beginning of long-term cooperation to make available products for patients that will be expanded in order to have stronger product portfolio together”.

Ethypharm is committed to pain management

Pain relief is nowadays considered a basic right that applies to every individual, managing pain is a major public health challenge in the 21st century. Today, 80 million adults in Europe suffer from chronic pain¹.

Based on recommendations from health authorities, learned societies and healthcare professionals ; Distribution of the analgesics Oxycodone and Hydromorphone is accompanied by information for both patients, prescribers and healthcare professionals to make them aware of the risks of addiction associated with opioids

The Ethypharm Group CEO Bertrand Deluard concluded, “Business development and in-licensing is fundamental to our strategy. We are very glad that our German subsidiary has been involved from start to finish in setting up this local partnership, and we are currently considering broadening the scope of our collaboration with Kalceks. This is fully consistent with the positioning of the Ethypharm Group as a specialty pharmaceutical company and demonstrates once again how involved it is in pain management.”

¹ Source: European Pain Federation – 2016 – www.europeanpainfederation.eu

*Except Midazolam



About Ethypharm

Ethypharm is a European-based specialty pharmaceutical company with global reach focusing on CNS (Pain, Addiction) and Critical Care. Those core therapeutic areas representing 64% of our 2018 revenue. Ethypharm is headquartered in France with an international team of 1,400 people mainly located in France, UK, Germany and China. The Group is also serving patients through his historical 100+ partners network in more than 80 countries.

For more than 40 years, Ethypharm employees work across the globe to make the difference for patients' lives, delivering our high-quality medicines responding to unmet medical needs.

Ethypharm closely collaborate with health authorities and healthcare professionals to ensure proper use and access to reliable medicines around the world.

To learn more about Ethypharm, please visit us at www.ethypharm.com and follow @ethypharm on LinkedIn.

If you want to partner with us, do not hesitate to contact our Business Development & In-Licensing team at: partner-with-us@ethypharm.com

About Kalceks

JSC Kalceks is European Union based pharmaceutical company with beginning operation in 1920. Specialise in generic products for the hospital segment. Over the years, by determinedly focusing on the hospital segment and have accumulated profound knowledge and experience in this area.

Kalceks mission is to make high-quality specialty pharmaceutical products available to people all over the world and actively expanding product range and global reach.

For more information: www.kalceks.com

Press contact

Avril PONNELLE / presse@ethypharm.com / +33 (0)1 41 12 17 20